Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,529 JPY | +0.39% | +1.09% | +8.83% |
Business Summary
Number of employees: 4,144
Sales per Business
JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Prescription Drugs
93.3
%
| 249,579 | 93.7 % | 260,235 | 93.3 % | +4.27% |
Over-the-counter Drugs
3.8
%
| 9,780 | 3.7 % | 10,628 | 3.8 % | +8.67% |
Medical Equipment
2.2
%
| 5,184 | 1.9 % | 6,257 | 2.2 % | +20.70% |
Others
0.7
%
| 1,714 | 0.6 % | 1,919 | 0.7 % | +11.96% |
Sales per region
JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Japan
63.6
%
| 173,633 | 65.2 % | 177,373 | 63.6 % | +2.15% |
EMEA
18.8
%
| 42,899 | 16.1 % | 52,513 | 18.8 % | +22.41% |
Asia
8.6
%
| 19,813 | 7.4 % | 24,118 | 8.6 % | +21.73% |
China
7.7
%
| 27,197 | 10.2 % | 21,546 | 7.7 % | -20.78% |
Americas
1.3
%
| 2,715 | 1.0 % | 3,488 | 1.3 % | +28.47% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Takeshi Ito
CEO | Chief Executive Officer | 64 | 82-03-31 |
Kazuo Koshiji
DFI | Director of Finance/CFO | - | - |
Akira Kurokawa
CHM | Chairman | 71 | 77-03-31 |
Mika Masunari
CMP | Compliance Officer | - | - |
Minori Hara
CTO | Chief Tech/Sci/R&D Officer | - | - |
Investor Relations Contact | - | - | |
Keizo Nakada
PRN | Corporate Officer/Principal | - | - |
Ippei Kurihara
SAM | Sales & Marketing | - | - |
Tomoki Yashiki
HRO | Human Resources Officer | - | - |
Hiro Izaka
AUD | Comptroller/Controller/Auditor | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Akira Kurokawa
CHM | Chairman | 71 | 77-03-31 |
Kanoko Oishi
BRD | Director/Board Member | 63 | 15-05-31 |
Noboru Kotani
BRD | Director/Board Member | 67 | 22-06-23 |
Yutaro Shintaku
BRD | Director/Board Member | 68 | 17-05-31 |
Director/Board Member | 69 | 18-05-31 | |
Takeshi Ito
CEO | Chief Executive Officer | 64 | 82-03-31 |
Tamie Minami
BRD | Director/Board Member | 65 | 22-06-23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 363,996,254 | 341,047,590 ( 93.70 %) | 12,792,169 ( 3.514 %) | 93.70 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
3,746,000 | 0.75% | 60,752,291 $ | |
EISAI CO., LTD. 0.32% | 949,500 | 0.32% | 38,997,598 $ |
737,469 | 0.20% | 7,487,007 $ | |
373,800 | 0.17% | 5,730,059 $ | |
259,040 | 0.00% | 2,664,939 $ | |
SEIKAGAKU CORPORATION 0.73% | 415,600 | 0.73% | 2,100,725 $ |
TOHO HOLDINGS CO., LTD. 0.09% | 69,050 | 0.09% | 1,666,197 $ |
QD LASER, INC. 1.06% | 444,480 | 1.06% | 1,597,657 $ |
SUZUKEN CO., LTD. 0.05% | 42,226 | 0.05% | 1,294,304 $ |
VITAL KSK HOLDINGS, INC. 0.25% | 128,474 | 0.25% | 1,066,195 $ |
Company contact information
Santen Pharmaceutical Co., Ltd.
Grand Front Osaka Tower A, 25/F 4-20 Ofuka-cho
530-8552, Osaka
+81 6 7664 8621
http://www.santen.co.jpGroup companies
Name | Category and Sector |
---|---|
Santen Oy
Santen Oy Pharmaceuticals: MajorHealth Technology Santen Oy engages in the development, research, manufacture and marketing of pharmaceuticals, over-the-counter products, and medical devices. It specializes in ophthalmic pharmaceuticals. The company was founded on February 28, 1997 and is headquartered in Tampere, Finland. |
Pharmaceuticals: Major
|
Santen Pharmaceutical Spain SL
Santen Pharmaceutical Spain SL Medical DistributorsDistribution Services Part of Santen Pharmaceutical Co., Ltd., Santen Pharmaceutical Spain SL wholesales pharmaceutical products. The private company is based in Las Rozas, Spain. |
Medical Distributors
|
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.83% | 3.64B | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
-3.40% | 157B |
- Stock Market
- Equities
- 4536 Stock
- Company Santen Pharmaceutical Co., Ltd.